There was a marked increase in the prevalence of targeted therapy among patients with chronic lymphocytic leukemia (CLL), which corresponded to positive overall survival rates observed in the study.
The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.
Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.